STOCK TITAN

LeMaitre Vascular (LMAT) DEF 14A Filings

LMAT NASDAQ

Here are the DEF 14A proxy statements from LeMaitre Vascular, Inc. (LMAT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LMAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMAT filings page.

Rhea-AI Summary

LeMaitre Vascular, Inc. is asking stockholders to vote at its 2026 annual meeting on June 2, 2026, in Burlington, Massachusetts. Investors will elect two Class II directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify Grant Thornton LLP as auditor for 2026.

The proxy highlights a seven‑member, largely independent board with extensive medical device and financial expertise, and describes governance practices such as a director resignation policy, clawback policy, insider trading restrictions, and board‑level risk oversight. It also discloses major shareholders and 2025 executive pay structure, which ties a significant portion of compensation to financial and operational performance.